Oruka Therapeutics, Inc. (ORKA)
NASDAQ: ORKA · Real-Time Price · USD
32.98
+0.01 (0.03%)
Mar 9, 2026, 2:12 PM EDT - Market open
Oruka Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2024 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 |
| Selling, General & Admin | 20.62 | 14.25 |
| Research & Development | 104.45 | 81.01 |
| Operating Expenses | 125.08 | 95.26 |
| Operating Income | -125.08 | -95.26 |
| Interest Expense | -0.13 | -1.6 |
| Interest & Investment Income | 16.85 | 6.4 |
| Other Non Operating Income (Expenses) | -0.01 | 0 |
| EBT Excluding Unusual Items | -108.37 | -90.46 |
| Other Unusual Items | -0.87 | -0.87 |
| Pretax Income | -109.24 | -91.34 |
| Net Income | -109.24 | -91.34 |
| Preferred Dividends & Other Adjustments | -25.67 | -20.39 |
| Net Income to Common | -83.57 | -70.95 |
| Shares Outstanding (Basic) | 43 | 17 |
| Shares Outstanding (Diluted) | 43 | 17 |
| EPS (Basic) | -1.95 | -4.23 |
| EPS (Diluted) | -1.95 | -4.23 |
| Free Cash Flow | -89.87 | -63.3 |
| Free Cash Flow Per Share | -2.09 | -3.77 |
| EBITDA | -125 | -95.23 |
| D&A For EBITDA | 0.07 | 0.03 |
| EBIT | -125.08 | -95.26 |
Source: S&P Capital IQ. Standard template.
Financial Sources.